910484-15-0

Basic information

• Product Name: Urea, N-[3,4-difluoro-2-(4-fluorobenzoyl)phenyl]-N'-(2,2,2-trifluoroethyl)-
• CAS NO: 910484-15-0
• Molecular Formula: C16H10F6N2O2
• Molecular Weight: 376.258
• Mol File: 910484-15-0.mol

Chemical Properties

• CAS DataBase Reference: Urea, N-[3,4-difluoro-2-(4-fluorobenzoyl)phenyl]-N'-(2,2,2-trifluoroethyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Urea, N-[3,4-difluoro-2-(4-fluorobenzoyl)phenyl]-N'-(2,2,2-trifluoroethyl)-(910484-15-0)
• EPA Substance Registry System: Urea, N-[3,4-difluoro-2-(4-fluorobenzoyl)phenyl]-N'-(2,2,2-trifluoroethyl)-(910484-15-0)

Safety Data

• Hazardous Substances Data: 910484-15-0(Hazardous Substances Data)

Upstream product

• 910484-14-9 (6-amino-2,3-difluorophenyl)(4-fluorophenyl)methanone 
• 753-90-2 trifluoroethylamine 
• 32315-10-9 bis(trichloromethyl) carbonate 
• 460-39-9 3,3,3-trifluoropropylamine 

Downstream Products

• 910484-16-1 5,6-difluoro-4-(4-fluorophenyl)-4-hydroxy-3-(2,2,2-trifluoroethyl)-3,4-dihydroquinazolin-2(1H)-one 

Relevant articles and documents

Discovery and expanded SAR of 4,4-disubstituted quinazolin-2-ones as potent T-type calcium channel antagonists

The discovery and synthesis of 4,4-disubstituted quinazolinones as T-type calcium channel antagonists is reported. Based on lead compounds 2 and 3, a focused SAR campaign driven by the optimization of potency, metabolic stability, and pharmacokinetic profile identified 45 as a potent T-type Ca2+ channel antagonist with minimized PXR activation. In vivo, 45 suppressed seizure frequency in a rat model of absence epilepsy and showed significant alterations of sleep architecture after oral dosing to rats as measured by EEG.

QUINAZOLINONE T-TYPE CALCIUM CHANNEL ANTAGONISTS

The present invention is directed to quinazolinone compounds which are antagonists of T-type calcium channels, and which are useful in the treatment or prevention of disorders and diseases in which T-type calcium channels are involved. The invention is al

QUINAZOLINONE T-TYPE CALCIUM CHANNEL ANTAGONISTS

The present invention is directed to quinazolinone compounds which are antagonists of T-type calcium channels, and which are useful in the treatment or prevention of disorders and diseases in which T-type calcium channels are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which T-type calcium channels are involved.